Table 2.
Reported EGFR alterations in gliosarcoma
| Referencesa | Number of cases analyzed for EGFR status | Methodologyb | EGFR status | Clinical outcomec |
|---|---|---|---|---|
| Reis et al. [9] | 19 | Differential PCR, Immunohistochemistry | No alterations (0/19) | Not available |
| Actor et al. [11] | 38 | Comparative genomic hybridization, Single-strand conformation polymorphism/heteroduplex analysis, Duplex PCR, Southern blot analysis |
Amplification (3/38) Strong + IHC (2/38)d |
Not available |
| Kleinschmidt-DeMasters et al. [24] | 1 | FISH | No amplification (0/1) | Overall survival (OS): 34 weeks |
| Lin et al. [28] | 7 | Immunohistochemistry | Strong + IHC (3/7)e |
Median progression free survival (PFS): 0–1+ (EGFR IHC Score): 17.2 months 2–3+ (EGFR IHC Score): 11.2 months Median Overall Survival (OS): 0–1+ (EGFR IHC Score): 20.4 months 2–3+ (EGFR IHC Score): 17.7 months |
| Yao et al. [25] | 1 | FISH | No amplification (0/1) | Not available |
| Cachia et al. [10] | 14 | PCR-based primer extension assay, Next Generation sequencing, Targeted gene whole exome DNA sequencing, Immunohistochemistry | c.1831G > A (1/19) | Case #4 outcome data not denoted, not able to separate EGFR from WT |
| Shelly et al. [26] | 31 | FISH | Amplification (1/31) | Outcome data not stratified by histology |
| Pain et al. [27] | 1 | Next generation DNA sequencing, CISH | EGFR G719D mutation (1/1) | Not available |
| Smith et al. [53] | 16 | Not available |
No amplification (0/9) No EGFRvIII mutation (0/7) |
Outcome data available, not stratified by EGFR status |
Summary of a literature review derived from a Scopus® search for the keywords "gliosarcoma and EGFR," from 1 January 1995 to 31 July 2018
EGFR epidermal growth factor receptor, PCR polymerase chain reaction, IHC immunohistochemistry, WT wild type, FISH Fluorescence in situ hybridization, CISH chromogenic in situ hybridization
aRefer to bibliography for full citation
bThe methodology used to detect EGFR alterations
cOverall survival of cases with EGFR alteration versus wildtype (WT)
dStrong immunohistochemical staining (3+) was detected in the glial component only in 2 of the 3 cases with EGFR amplification
eStrong immunohistochemical staining (3+) was detected in the sarcomatous component in 3 of 7 cases